Vaccine Application Extends Life of Metastatic Prostate Cancer Patients
|
By LabMedica International staff writers Posted on 24 Feb 2010 |
|
In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to trigger an immune system attack on prostate tumor cells lived considerably longer than patients who received a placebo vaccine.
The study's findings were published by the Journal of Clinical Oncology on its website in January 2010, and scheduled for later print publication. The randomized phase II study was performed by researchers from the Dana-Farber Cancer Institute (Boston, MA, USA) and affiliated organizations. The study involved the PROSTVAC-VF vaccine, a combination of two weakened poxviruses that have been genetically programmed to produce slightly irregular versions of prostate specific antigen (PSA)--a protein on the surface of prostate cells that is abnormal in many prostate cancers--and three costimulatory molecules that spur the immune system to a more vigorous attack on tumor cells.
The double-blinded trial included 125 patients with metastatic prostate cancer who did not respond to standard, hormone-lowering therapy. Eighty-two of the participants received the vaccine, produced by BN ImmunoTherapeutics, Inc. (Mountain View, CA, USA), and 40 received a placebo.
At the three-year point after the study, 30% of the PROSTVAC-VF patients were alive, versus 17% of the control group. The median survival of the vaccine group was 24.5 months, compared to 16 months for the control group, an 8.5-month increase.
Patients tolerated the vaccine well; only a small number experienced side effects such as fatigue, fevers, and nausea. "Although this study is relatively small, it offers encouraging evidence of a clinically meaningful benefit from this vaccine approach,” said lead investigator and lead author Philip Kantoff, M.D., of Dana-Farber, who helped design the trial.
Investigators are now planning a phase III trial that will enroll about 600 patients to evaluate further the vaccine's effectiveness.
Related Links:
Dana-Farber Cancer Institute
BN ImmunoTherapeutics
The study's findings were published by the Journal of Clinical Oncology on its website in January 2010, and scheduled for later print publication. The randomized phase II study was performed by researchers from the Dana-Farber Cancer Institute (Boston, MA, USA) and affiliated organizations. The study involved the PROSTVAC-VF vaccine, a combination of two weakened poxviruses that have been genetically programmed to produce slightly irregular versions of prostate specific antigen (PSA)--a protein on the surface of prostate cells that is abnormal in many prostate cancers--and three costimulatory molecules that spur the immune system to a more vigorous attack on tumor cells.
The double-blinded trial included 125 patients with metastatic prostate cancer who did not respond to standard, hormone-lowering therapy. Eighty-two of the participants received the vaccine, produced by BN ImmunoTherapeutics, Inc. (Mountain View, CA, USA), and 40 received a placebo.
At the three-year point after the study, 30% of the PROSTVAC-VF patients were alive, versus 17% of the control group. The median survival of the vaccine group was 24.5 months, compared to 16 months for the control group, an 8.5-month increase.
Patients tolerated the vaccine well; only a small number experienced side effects such as fatigue, fevers, and nausea. "Although this study is relatively small, it offers encouraging evidence of a clinically meaningful benefit from this vaccine approach,” said lead investigator and lead author Philip Kantoff, M.D., of Dana-Farber, who helped design the trial.
Investigators are now planning a phase III trial that will enroll about 600 patients to evaluate further the vaccine's effectiveness.
Related Links:
Dana-Farber Cancer Institute
BN ImmunoTherapeutics
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read moreMolecular Diagnostics
view channel
Novel Immune-Based Biomarker Helps Detect Ovarian Cancer Years before Diagnosis
High-grade ovarian cancer (HGOC) ranks as the fifth-leading cause of cancer-related death among women. Over 90% of cases are diagnosed at advanced stages after the cancer has spread, posing significant... Read more
New Blood Test Identifies Children with Rare Heart Condition
Hypertrophic cardiomyopathy (HCM) is a hereditary condition that leads to the thickening of the heart muscle and is the most frequent cause of sudden death among children and teenagers. There is no cure... Read more
Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods
Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more
Hematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel.jpg "Image: The AI tool predicts whether someone’s cancer will respond to immune checkpoint inhibitors (Photo courtesy of National Cancer Institute)")
AI Tool Predicts Cancer Patients’ Response to Immunotherapy
Immune checkpoint inhibitors are a form of immunotherapy drug that enables immune cells to target and destroy cancer cells. At present, the Food and Drug Administration has approved two predictive biomarkers... Read more
Molecular Profiling Improves Diagnosis for Children with High Risk Cancers
Cancer remains the leading cause of disease-related death among children in most developed nations, and approximately one-fourth of these patients are diagnosed with aggressive, high-risk, or relapsed... Read more
.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
Microbiology
view channel
Rapid UTI Test Cuts Detection Time from 3 days to 45 Minutes
Antimicrobial Resistance (AMR), also known as antibiotic resistance or superbugs, is a silent but growing pandemic where bacteria have become resistant to lifesaving antibiotics due to decades of overuse and misuse.... Read more
POC STI Test Shortens Time from ED Arrival to Test Results
In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read morePathology
view channel
New Technique Reveals Earliest Signs of Genetic Mutations
Mutations are alterations in the molecular "letters" that constitute the DNA code, which serves as the blueprint for all living cells. While some of these changes may be inconsequential, others can lead... Read more
New WHO Reporting System for Lung Cytopathology to Enhance Diagnostic Accuracy
Lung cancer continues to be the most common cause of cancer-related deaths worldwide and ranks as the second most frequently diagnosed cancer in both men and women. The role of lung cytopathology, which... Read more
Self-Taught AI Tool Diagnoses and Predicts Severity of Common Lung Cancer
A computer program powered by artificial intelligence (AI) and trained on nearly half a million tissue images can effectively diagnose cases of adenocarcinoma, the most prevalent type of lung cancer.... Read more
Novel AI-Powered Method for Tissue Analysis Improves Understanding of Disease Pathology
Scientists at Brown University (Providence, RI, USA) and the University of Michigan (Ann Arbor, MI, USA) have created a groundbreaking computational technique to examine complex tissue data, potentially... Read moreTechnology
view channel
Microneedle Patch Detects Skin Cancer Early
Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes.... Read more
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
Industry
view channel
Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing
Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
